Adeno Associated Virus Vector Manufacturing Market Size, Share, Growth, Trends | Report 2023-2032
The global adeno associated virus vector manufacturing market was estimated at USD 11 billion in 2022 and it is expected to surpass around USD 28.65 billion by 2032, poised to grow at a CAGR of 10.04% from 2023 to 2032.
The adeno associated virus vector manufacturing market is anticipated to witness significant growth owing to its simple structure, lack of disease correlation, and unique biology which has also gained huge interest in the healthcare community. Moreover, several AVV-based therapies have been developed for the treatment of diseases such as cystic fibrosis, Duchenne muscular dystrophy, and retinitis pigmentosa. For instance, in October 2022, Taysha GTx. and Astellas Pharma Inc announced to offer funding to support the advancement of Taysha's AAV gene therapy development program for the treatment of giant axonal neuropathy (GAN) and Rett syndrome.
Report Scope of the Adeno Associated Virus Vector Manufacturing Market
| Report Coverage | Details |
| Market Size in 2022 | USD 11 billion |
| Revenue Forecast by 2032 | USD 28.65 billion |
| Growth rate from 2023 to 2032 | CAGR of 10.04% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Furthermore, advancements in the efficiency of gene delivery to treat diseases through adeno-associated viruses along with the advances in manufacturing approaches have accelerated interest in drug development for gene therapies. In February 2021, an article published by Wyss Institute stated that adeno-associated virus has been considered as the primary vector for in vivo delivery of therapeutic genes as they are non-pathogenic and it can effectively target several tissue and cell types. FDA authorized several vector-based gene therapies for spinal muscular atrophy treatment and rare retinal dystrophy treatment that highlights the promise of the therapeutic modality.
Moreover, according to FDA, approximately 10-20 gene therapy products will be authorized by 2025. The increase in the development of these therapies could be due to the introduction of effective and safe gene delivery vectors like an adeno-associated virus. The significant potential of the vector has been determined by the authorization of two AAV-based gene therapy products and its use in more than 100 clinical trials. Despite its potential application in certain clinical settings, the use of AAV-based gene therapy remains limited due to issues linked to host immunity. This may be one of the factor which could restrict the Adeno Associated Virus vector (AAV) manufacturing market growth.
Several developments by the market players such as new product launches, mergers, and acquisitions have positively impacted the market growth. For instance, In August 2022, Merck KGaA announced of launching the VirusExpress 293 adeno-associated virus production platform, which makes the company CDMO and a technology developer to offer full viral vector manufacturing, including Lentiviral, CTO, CDMO, and process development. This would help biopharmaceutical companies to enhance the speed of clinical manufacturing while lowering process development costs and time.
Major players operating in the AAV vector manufacturing market include Roche (Spark Therapeutics), Biomarin Pharmaceutical, Oxford BioMedica, WuXi AppTec, YPOSKESI, Sarepta Therapeutics, Pfizer, Audentes Therapeutics.
Adeno Associated Virus Vector Manufacturing Market Segmentations:
| By Scale of operations | By Application | By Therapeutic Area | By Gene Delivery Method |
|
Clinical Preclinical Commercial |
Cell Therapy Gene Therapy Vaccine |
Hematological Diseases Infectious Diseases Genetic Disorders Neurological Disorders Ophthalmic Disorders Others |
In Vivo In Vitro |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Adeno Associated Virus Vector Manufacturing Market
5.1. COVID-19 Landscape: Adeno Associated Virus Vector Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Adeno Associated Virus Vector Manufacturing Market, By Scale of operations
8.1. Adeno Associated Virus Vector Manufacturing Market, by Scale of operations, 2023-2032
8.1.1. Clinical
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Preclinical
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Commercial
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Adeno Associated Virus Vector Manufacturing Market, By Application
9.1. Adeno Associated Virus Vector Manufacturing Market, by Application, 2023-2032
9.1.1. Cell Therapy
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Gene Therapy
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Vaccine
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Adeno Associated Virus Vector Manufacturing Market, By Therapeutic Area
10.1. Adeno Associated Virus Vector Manufacturing Market, by Therapeutic Area, 2023-2032
10.1.1. Hematological Diseases
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Infectious Diseases
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Genetic Disorders
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Neurological Disorders
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Ophthalmic Disorders
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Adeno Associated Virus Vector Manufacturing Market, By Gene Delivery Method
11.1. Adeno Associated Virus Vector Manufacturing Market, by Gene Delivery Method, 2023-2032
11.1.1. In Vivo
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. In Vitro
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Adeno Associated Virus Vector Manufacturing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Scale of operations (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Gene Delivery Method (2020-2032)
Chapter 13. Company Profiles
13.1. Roche (Spark Therapeutics)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Biomarin Pharmaceutical
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Oxford BioMedica
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. WuXi AppTec
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. YPOSKESI
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Sarepta Therapeutics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pfizer
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Audentes Therapeutics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers